Nervgen Pharma Corp (NGEN.VN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in thousands)
| 12-2025 | 09-2025 | 06-2025 | 03-2025 | 12-2024 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 22,070 | 11,364 | 15,675 | 14,471 | 17,267 |
| Marketable Securities | 8 | 33 | 58 | 82 | 97 |
| Receivables | 81 | 344 | 97 | 334 | 415 |
| Other current assets | 642 | 311 | 293 | 68 | 516 |
| TOTAL | $22,800 | $12,654 | $16,487 | $15,388 | $19,013 |
| Non-Current Assets | |||||
| Investments And Advances | 0 | 0 | 0 | 0 | 8 |
| Intangibles | 409 | 423 | 437 | 451 | 465 |
| TOTAL | $409 | $423 | $437 | $451 | $473 |
| Total Assets | $23,210 | $13,077 | $16,924 | $15,839 | $19,486 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accrued Expenses | 3,267 | 4,335 | 4,118 | 3,826 | 3,745 |
| Other current liabilities | 15,067 | 10,580 | 12,563 | 9,866 | 11,863 |
| TOTAL | $19,733 | $16,019 | $17,842 | $14,449 | $16,901 |
| Non-Current Liabilities | |||||
| TOTAL | $0 | $0 | $0 | $0 | $8 |
| Total Liabilities | $19,733 | $16,019 | $17,842 | $14,449 | $16,910 |
| Shareholders' Equity | |||||
| Common Shares | 102,999 | 90,483 | 88,418 | 82,411 | 81,100 |
| Retained earnings | -146,764 | -119,855 | -115,211 | -106,107 | -102,159 |
| Other shareholders' equity | 47,241 | 26,430 | 25,875 | 25,085 | 23,636 |
| TOTAL | $3,477 | $-2,942 | $-918 | $1,389 | $2,577 |
| Total Liabilities And Equity | $23,210 | $13,077 | $16,924 | $15,839 | $19,486 |